A Bayesian design for phase I cancer therapeutic vaccine trials

Research output: Contribution to journalArticle

Abstract

Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include determining whether the vaccine shows biologic activity and the minimum dose necessary to achieve a full immune or even clinical response. In this paper, we propose a new Bayesian phase I trial design that allows simultaneous evaluation of safety and immunogenicity outcomes. We demonstrate the proposed clinical trial design by both a numeric study and a therapeutic human papillomavirus vaccine trial.

Original languageEnglish (US)
JournalStatistics in Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Bayesian Design
Cancer Vaccines
Vaccine
Phase I Trial
Cancer
Vaccines
Drugs
Safety
Papillomavirus Vaccines
Clinical Trials, Phase I
Clinical Trials
Cytotoxins
Drug Combinations
Pharmaceutical Preparations
Therapeutics
Toxicity
Numerics
Dose
Necessary
Design

Keywords

  • Bayesian
  • cancer therapeutic vaccine
  • clinical trial
  • HPV
  • Phase I

ASJC Scopus subject areas

  • Epidemiology
  • Statistics and Probability

Cite this

@article{c1632c006a154a86929cdb8bc545dee7,
title = "A Bayesian design for phase I cancer therapeutic vaccine trials",
abstract = "Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include determining whether the vaccine shows biologic activity and the minimum dose necessary to achieve a full immune or even clinical response. In this paper, we propose a new Bayesian phase I trial design that allows simultaneous evaluation of safety and immunogenicity outcomes. We demonstrate the proposed clinical trial design by both a numeric study and a therapeutic human papillomavirus vaccine trial.",
keywords = "Bayesian, cancer therapeutic vaccine, clinical trial, HPV, Phase I",
author = "Chenguang Wang and Gary Rosner and Roden, {Richard S}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/sim.8021",
language = "English (US)",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - A Bayesian design for phase I cancer therapeutic vaccine trials

AU - Wang, Chenguang

AU - Rosner, Gary

AU - Roden, Richard S

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include determining whether the vaccine shows biologic activity and the minimum dose necessary to achieve a full immune or even clinical response. In this paper, we propose a new Bayesian phase I trial design that allows simultaneous evaluation of safety and immunogenicity outcomes. We demonstrate the proposed clinical trial design by both a numeric study and a therapeutic human papillomavirus vaccine trial.

AB - Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include determining whether the vaccine shows biologic activity and the minimum dose necessary to achieve a full immune or even clinical response. In this paper, we propose a new Bayesian phase I trial design that allows simultaneous evaluation of safety and immunogenicity outcomes. We demonstrate the proposed clinical trial design by both a numeric study and a therapeutic human papillomavirus vaccine trial.

KW - Bayesian

KW - cancer therapeutic vaccine

KW - clinical trial

KW - HPV

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=85055700377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055700377&partnerID=8YFLogxK

U2 - 10.1002/sim.8021

DO - 10.1002/sim.8021

M3 - Article

C2 - 30368868

AN - SCOPUS:85055700377

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

ER -